TABLE 1.
Patient Demographics and Documented Indication for Dupilumab (n=33)
| VARIABLES | FREQUENCY (%) |
|---|---|
| Age (yrs), mean ± SD | 46 ± 15.4 |
| Body Mass Index, mean ± SD | 28.8 ± 6.8 |
| Sex | |
| Female | 28 (84.8%) |
| Race | |
| White | 18 (54.5%) |
| Black | 5 (15.2%) |
| Asian | 4 (12.1%) |
| Other/declined/not specified | 6 (18.2%) |
| Comorbidities | |
| Angioedema | 7 (21.2%) |
| AD | 21 (63.6%) |
| Asthma | 20 (60.6%) |
| CRSwNP | 3 (9.1%) |
| EoE | 2 (6.1%) |
| Documented Indication for Dupilumab | |
| AD (moderate-severe) | 19 (57.6%) |
| Asthma (moderate-severe, persistent) | 9 (27.3%) |
| CRSwNP | 1 (3%) |
| Asthma and CRSwNP | 2 (6.1%) |
| EoE | 2 (6.1) |
AD: atopic dermatitis, CRSwNP: chronic rhinosinusitis with nasal polyps, EoE: eosinophilic esophagitis